Greg Fluet

Greg is currently Chief Operating Officer for Rebiotix, a Ferring Pharmaceuticals company. Since November 2016 he has been on the team at Rebiotix in both contract and permanent roles including Chief Business Officer at Rebiotix, Inc., until its acquisition by Ferring Pharmaceuticals in April 2018.

Prior to that Greg had a strategic consulting practice working with startup life science companies. He had previously served as chief executive officer at Urologix, Inc., then a public company, from 2012 to January 2016. He also served as its interim chief financial officer from August 2014 to May 2015 and as its executive vice president and chief operating officer from 2008 to 2012. From 2002 to 2008, he was employed as an associate at Sapient Capital Management, LLC, a healthcare focused venture capital fund. He received a BS in Mechanical Engineering from Stanford University.